Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 11/2020

01-11-2020 | Systemic Lupus Erythematosus | Review Article

The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach

Authors: Sahar Najafi, Elham Rajaei, Rezvan Moallemian, Forough Nokhostin

Published in: Clinical Rheumatology | Issue 11/2020

Login to get access

Abstract

Cytokine pathways and their signaling disorders can be the cause of onset and pathogenesis of many diseases such as autoimmune diseases and COVID-19 infection. Autoimmune patients may be at higher risk of developing infection due to the impaired immune responses, the use of immunosuppressive drugs, and damage to various organs. Increased secretion of inflammatory cytokines and intolerance of the patient’s immune system to COVID-19 infection are the leading causes of hospitalization of these patients. The content used in this paper has been taken from English language articles (2005–2020) retrieved from the PubMed database and Google Scholar search engine using “COVID-19,” “Autoimmune disease,” “Therapeutic,” “Pathogenesis,” and “Pathway” keywords. The emergence of COVID-19 and its association with autoimmune disorders is a major challenge in the management of these diseases. The results showed that the use of corticosteroids in the treatment of autoimmune diseases can make diagnosis and treatment of COVID-19 more challenging by preventing the fever. Due to the common pathogenesis of COVID-19 and autoimmune diseases, the use of autoimmune drugs as a possible treatment option could help control the virus.

Key Points

• Inflammatory cytokines play an essential role in the pathogenesis of COVID-19
• ACE2 dysfunctions are related to the with COVID-19 and autoimmune diseases
• The use autoimmune diseases drugs can be useful in treating COVID-19
Literature
1.
2.
Nokhostin F, DargahiMalAmir M, Tutunchi S, Rezaeeyan H (2020) Evaluation of prognostic/diagnostic value of Hematological markers in the detection of inflammation in coronavirus disease: a review study. J Adv Med Biomed Res. 28(128):171–174CrossRef
3.
Thienemann F, Pinto F, Grobbee DE, Boehm M, Bazargani N, Ge J, Sliwa K (2020) World heart federation briefing on prevention: coronavirus disease 2019 (COVID-19) in low-income countries. Glob Heart 15(1):31PubMedPubMedCentralCrossRef
4.
Lei J, Li J, Li X, Qi X (2020) CT imaging of the 2019 novel coronavirus (2019-nCoV) pneumonia. Radiology. 295(1):18PubMedCrossRef
5.
Kyttaris VC (2019) Targeting cytokines to treat autoimmunity. Clin Immunol (Orlando, Fla) 206:108251CrossRef
6.
Bogoch II, Watts A, Thomas-Bachli A, Huber C, Kraemer MUG, Khan K (2020) Pneumonia of unknown aetiology in Wuhan, China: potential for international spread via commercial air travel. J Travel Med 27(2)
7.
Hemminki K, Huang W, Sundquist J, Sundquist K, Ji J (2020) Autoimmune diseases and hematological malignancies: exploring the underlying mechanisms from epidemiological evidence. Semin Cancer Biol 64:114–121PubMedCrossRef
8.
Patra MC, Shah M, Choi S (2020) Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases. Semin Cancer Biol 64:61–82PubMedCrossRef
9.
Valencia JC, Egbukichi N, Erwin-Cohen RA (2019) Autoimmunity and Cancer, the paradox comorbidities challenging therapy in the context of preexisting autoimmunity. J Interf Cytokine Res 39(1):72–84CrossRef
10.
Kuhn A, Bonsmann G, Anders HJ, Herzer P, Tenbrock K, Schneider M (2015 Jun) The diagnosis and treatment of systemic lupus erythematosus. Dtsch Arztebl Int 112(25):423PubMedPubMedCentral
11.
Iliopoulos AG, Tsokos GC Immunopathogenesis and spectrum of infections in systemiclupus erythematosus. InSeminars in arthritis and rheumatism 1996 Apr 1 (Vol. 25, no. 5, pp. 318–336). WB Saunders
12.
Rúa-Figueroa Í, López-Longo J, Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A et al (2017) Incidence, associated factors and clinical impact of severe infections in a large, multicentric cohort of patients with systemic lupus erythematosus. Semin Arthritis Rheum 47(1):38–45PubMedCrossRef
13.
Thomas G, Mancini J, Jourde-Chiche N, Sarlon G, Amoura Z, Harlé JR, Jougla E, Chiche L (2014 Sep) Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol 66(9):2503–2511
14.
Oke V, Brauner S, Larsson A, Gustafsson J, Zickert A, Gunnarsson I, Svenungsson E (2017) IFN-λ1 with Th17 axis cytokines and IFN-α define different subsets in systemic lupus erythematosus (SLE). Arthritis Res Ther 19(1):139PubMedPubMedCentralCrossRef
15.
Zickert A, Amoudruz P, Sundström Y, Rönnelid J, Malmström V, Gunnarsson I (2015) IL-17 and IL-23 in lupus nephritis - association to histopathology and response to treatment. BMC Immunol 16(1):7PubMedPubMedCentralCrossRef
16.
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet (London, England) 395(10223):497–506CrossRef
17.
Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, Liu S, Zhao P, Liu H, Zhu L, Tai Y, Bai C, Gao T, Song J, Xia P, Dong J, Zhao J, Wang FS (2020) Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med 8(4):420–422PubMedPubMedCentralCrossRef
18.
Awasthi A, Kuchroo VK (2009 Aug 21) The yin and yang of follicular helper T cells. Science. 325(5943):953–955PubMedCrossRef
19.
Zhang Y, Li Y, Lv TT, Yin ZJ, Wang XB (2015 Aug) Elevated circulating Th17 and follicular helper CD4+ T cells in patients with rheumatoid arthritis. Apmis. 123(8):659–666PubMedCrossRef
20.
Terrier B, Costedoat-Chalumeau N, Garrido M, Geri G, Rosenzwajg M, Musset L, Klatzmann D, Saadoun D, Cacoub P (2012 Sep 1) Interleukin 21 correlates with T cell and B cell subset alterations in systemic lupus erythematosus. J Rheumatol 39(9):1819–1828
21.
Feng X, Wang D, Chen J, Lu L, Hua B, Li X, Tsao BP, Sun L (2012 Dec 17) Inhibition of aberrant circulating Tfh cell proportions by corticosteroids in patients with systemic lupus erythematosus. PLoS One 7(12):e51982PubMedPubMedCentralCrossRef
22.
Blanco P, Ueno H, Schmitt N (2016 Feb) T follicular helper (Tfh) cells in lupus: activation and involvement in SLE pathogenesis. Eur J Immunol 46(2):281–290PubMedCrossRef
23.
Wu D, Yang XO (2020) TH17 responses in cytokine storm of COVID-19: an emerging target of JAK2 inhibitor Fedratinib. Journal of microbiology, immunology, and infection =. Wei mian yu gan ran za zhi 53(3):368–370PubMedCrossRef
24.
Tse GM, Two KF, Chan PK, Lo AW, Ng KC, Wu A et al (2004) Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 57(3):260–265PubMedPubMedCentralCrossRef
25.
Uhlar CM, Whitehead AS (1999) Serum amyloid a, the major vertebrate acute-phase reactant. Eur J Biochem 265(2):501–523PubMedCrossRef
26.
Jovanović DB (2004) Clinical importance of determination of serum amyloid a. Srp Arh Celok Lek 132(7–8):267–271PubMedCrossRef
27.
Sano T, Huang W, Hall JA, Yang Y, Chen A, Gavzy SJ, et al. (2015) An IL-23R/IL-22 circuit regulates epithelial serum amyloid A to promote local effector Th17 responses. 163(2):381–93
28.
Sodin-Semrl S, Zigon P, Cucnik S, Kveder T, Blinc A, Tomsic M et al (2006) Serum amyloid a in autoimmune thrombosis. Autoimmun Rev 6(1):21–27PubMedCrossRef
29.
Chait A, Han CY, Oram JF, Heinecke JW (2005) Thematic review series: the immune system and atherogenesis. Lipoprotein-associated inflammatory proteins: markers or mediators of cardiovascular disease? J Lipid Res 46(3):389–403PubMedCrossRef
30.
Chen L, Lou J, Bai Y, Wang M (2020) COVID-19 disease with positive fecal and negative pharyngeal and sputum viral tests. Am J Gastroenterol 115(5):790PubMedCrossRef
31.
Cunnane G (2001) Amyloid precursors and amyloidosis in inflammatory arthritis. Curr Opin Rheumatol 13(1):67–73PubMedCrossRef
32.
Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood. 135(23):2033–2040PubMedCrossRef
33.
Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, Zhang X, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J, Ning Q (2020) Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest 130(5):2620–2629PubMedPubMedCentralCrossRef
34.
Arachchillage DRJ, Laffan M (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(5):1233–1234PubMedPubMedCentralCrossRef
35.
Carty CL, Heagerty P, Heckbert SR, Jarvik GP, Lange LA, Cushman M, Tracy RP, Reiner AP (2010) Interaction between fibrinogen and IL-6 genetic variants and associations with cardiovascular disease risk in the cardiovascular health study. Ann Hum Genet 74(1):1–10PubMedPubMedCentralCrossRef
36.
Zadeh FJ, Janatmakan F, Soltanzadeh M, Zamankhani MJA, medicine p (2019) Investigating the Effect of Fibrinogen Injection on Bleeding in Coronary Artery Bypass Surgery: A Clinical Trial. 9(4)
37.
Ferrario CM, Jessup J, Chappell MC, Averill DB, Brosnihan KB, Tallant EA, Diz DI, Gallagher PE (2005) Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2. Circulation. 111(20):2605–2610PubMedCrossRef
38.
Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS et al (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet (London, England) 395(10234):1417–1418
39.
Monti S, Montecucco C (2020) Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: ‘Does hydroxychloroquine prevent the transmission of COVID-19?’ by Heldwein and Calado and ‘SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment’ by Joob and Wiwanitkit. Ann Rheum Dis 79(6):e62PubMedCrossRef
40.
Bruce-Chwatt LJ, Black RH, Canfield CJ, Clyde DF (1986) Peters W. World Health Organization. Chemotherapy of malaria. World Health Organization, Wernsdorfer WH
41.
Devaux CA, Rolain JM, Colson P, Raoult D (2020) New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Int J Antimicrob Agents 55(5):105938PubMedPubMedCentralCrossRef
42.
White NJ, Pukrittayakamee S, Hien TT, Faiz MA, Mokuolu OA, Dondorp AMJTL (2014) Malaria. 383(9918):723–735
43.
Hosseini S, YousefiVarazgaei M, Ebrahimi M (2020) Effect of different doses of vitamin a on Î2-HCG production in patients suffering from gestational trophoblastic disease. J Adv Med Biomed Res. 28(128):151–155
44.
Zadeh FJ, Moadeli M, Soltanzadeh M, Janatmakan F (2017 Aug) Effect of remote ischemic preconditioning on troponin I in CABG. Anesth Pain Med. 7(4)
45.
Xiong Y, Liu Y, Cao L, Wang D, Guo M, Jiang A, Guo D, Hu W, Yang J, Tang Z, Wu H, Lin Y, Zhang M, Zhang Q, Shi M, Liu Y, Zhou Y, Lan K, Chen Y (2020) Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients. Emerging Microbes Infect 9(1):761–770CrossRef
46.
Saxena V, Lienesch DW, Zhou M, Bommireddy R, Azhar M, Doetschman T et al (2008) Dual roles of immunoregulatory cytokine TGF-beta in the pathogenesis of autoimmunity-mediated organ damage. J Immunol (Baltimore, Md : 1950) 180(3):1903–1912CrossRef
47.
Yu X, Buttgereit A, Lelios I, Utz SG, Cansever D, Becher B et al (2017) The cytokine TGF-β promotes the development and homeostasis of alveolar macrophages. Immunity 47(5):903–12.e4PubMedCrossRef
48.
Channappanavar R, Fehr AR, Vijay R, Mack M, Zhao J, Meyerholz DK, Perlman S (2016) Dysregulated type I interferon and inflammatory monocyte-macrophage responses cause lethal pneumonia in SARS-CoV-infected mice. Cell Host Microbe 19(2):181–193PubMedPubMedCentralCrossRef
49.
Perl A, Gergely P Jr, Nagy G, Koncz A, Banki K (2004) Mitochondrial hyperpolarization: a checkpoint of T-cell life, death and autoimmunity. Trends Immunol 25(7):360–367PubMedPubMedCentralCrossRef
50.
51.
52.
53.
Javaherforooshzadeh F, Monajemzadeh SA, Soltanzadeh M, Janatmakan F, Salari A, Saeed H (2018 Apr) A comparative study of the amount of bleeding and hemodynamic changes between dexmedetomidine infusion and remifentanil infusion for controlled hypotensive anesthesia in lumbar discopathy surgery: a double-blind, randomized, clinical trial. Anesth Pain Med. 8(2)
54.
Zhang C, He H, Wang L, Zhang N, Huang H, Xiong Q et al (2017) Virus-triggered ATP release limits viral replication through facilitating IFN-β production in a P2X7-dependent manner. J Immunol (Baltimore, Md : 1950) 199(4):1372–1381CrossRef
55.
Seif F, Khoshmirsafa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M (2017) The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal 15(1):23PubMedPubMedCentralCrossRef
56.
57.
Peng L, Oganesyan V, Wu H, Dall'Acqua WF, Damschroder MM (2015) Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody. mAbs 7(2):428–439PubMedPubMedCentralCrossRef
58.
Furie R, Khamashta M, Merrill JT, Werth VP, Kalunian K, Brohawn P et al (2017) Anifrolumab, an anti-interferon-α receptor monoclonal antibody, in moderate-to-severe systemic lupus erythematosus. Arthritis Rheumatol (Hoboken, NJ) 69(2):376–386CrossRef
59.
Yao X, Ye F, Zhang M, Cui C, Huang B, Niu P, Liu X, Zhao L, Dong E, Song C, Zhan S, Lu R, Li H, Tan W, Liu D (2020) In vitro antiviral activity and projection of optimized dosing Design of Hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 71:732–739PubMedCrossRef
60.
Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, Shi Z, Hu Z, Zhong W, Xiao G (2020 Mar) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 30(3):269–271
61.
Biot C, Daher W, Chavain N, Fandeur T, Khalife J, Dive D, et al. (2006) Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities. J Med Chem 49(9):2845–9
62.
Mathian A, Mahevas M, Rohmer J, Roumier M, Cohen-Aubart F, Amador-Borrero B, Barrelet A, Chauvet C, Chazal T, Delahousse M, Devaux M, Euvrard R, Fadlallah J, Florens N, Haroche J, Hié M, Juillard L, Lhote R, Maillet T, Richard-Colmant G, Palluy JB, Pha M, Perard L, Remy P, Rivière E, Sène D, Sève P, Morélot-Panzini C, Viallard JF, Virot JS, Benameur N, Zahr N, Yssel H, Godeau B, Amoura Z (2020) Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine. Ann Rheum Dis 79(6):837–839PubMedCrossRef
63.
Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, Zhuang R, Hu B, Zhang Z. Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. MedRxiv. 2020 Jan 1
64.
Favalli EG, Ingegnoli F, De Lucia O, Cincinelli G, Cimaz R, Caporali R (2020) COVID-19 infection and rheumatoid arthritis: Faraway, so close! Autoimmun Rev 19(5):102523PubMedPubMedCentralCrossRef
65.
Buch M, Emery P (2002) The aetiology and pathogenesis of rheumatoid arthritis. Hosp Pharm-London 9(1):5–10
66.
67.
Firestein GS, McInnes IB (2017 Feb 21) Immunopathogenesis of rheumatoid arthritis. Immunity. 46(2):183–196
68.
Muniyappa R, Gubbi S (2020) COVID-19 pandemic, coronaviruses, and diabetes mellitus. Am J Physiol Endocrinol Metab 318(5):E736–Ee41
69.
Hürlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O et al (2002) Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. Circulation. 106(17):2184–2187PubMedCrossRef
70.
Cheetham C, O'Driscoll G, Stanton K, Taylor R, Green D (2001) Losartan, an angiotensin type I receptor antagonist, improves conduit vessel endothelial function in Type II diabetes. Clin Sci (London, England : 1979) 100(1):13–17CrossRef
71.
Flammer AJ, Sudano I, Hermann F, Gay S, Forster A, Neidhart M, Künzler P, Enseleit F, Périat D, Hermann M, Nussberger J, Luscher TF, Corti R, Noll G, Ruschitzka F (2008) Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis. Circulation. 117(17):2262–2269PubMedCrossRef
72.
Nakamura A, Johns EJ, Imaizumi A, Yanagawa Y, Kohsaka T (1999) Effect of beta(2)-adrenoceptor activation and angiotensin II on tumour necrosis factor and interleukin 6 gene transcription in the rat renal resident macrophage cells. Cytokine. 11(10):759–765PubMedCrossRef
73.
Walsh DA, Suzuki T, Knock GA, Blake DR, Polak JM, Wharton J (1994) AT1 receptor characteristics of angiotensin analogue binding in human synovium. Br J Pharmacol 112(2):435–442PubMedPubMedCentralCrossRef
74.
Huang F, Guo J, Zou Z, Liu J, Cao B, Zhang S, Li H, Wang W, Sheng M, Liu S, Pan J, Bao C, Zeng M, Xiao H, Qian G, Hu X, Chen Y, Chen Y, Zhao Y, Liu Q, Zhou H, Zhu J, Gao H, Yang S, Liu X, Zheng S, Yang J, Diao H, Cao H, Wu Y, Zhao M, Tan S, Guo D, Zhao X, Ye Y, Wu W, Xu Y, Penninger JM, Li D, Gao GF, Jiang C, Li L (2014) Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients. Nat Commun 5:3595PubMedCrossRef
75.
Imai Y, Kuba K, Rao S, Huan Y, Guo F, Guan B, Yang P, Sarao R, Wada T, Leong-Poi H, Crackower MA, Fukamizu A, Hui CC, Hein L, Uhlig S, Slutsky AS, Jiang C, Penninger JM (2005) Angiotensin-converting enzyme 2 protects from severe acute lung failure. Nature. 436(7047):112–116PubMedPubMedCentralCrossRef
76.
Kuba K, Imai Y, Rao S, Gao H, Guo F, Guan B, Huan Y, Yang P, Zhang Y, Deng W, Bao L, Zhang B, Liu G, Wang Z, Chappell M, Liu Y, Zheng D, Leibbrandt A, Wada T, Slutsky AS, Liu D, Qin C, Jiang C, Penninger JM (2005) A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury. Nat Med 11(8):875–879PubMedPubMedCentralCrossRef
77.
Goto M, Fujisawa M, Yamada A, Okabe T, Takaku F, Sasano M, Nishioka K (1990) Spontaneous release of angiotensin converting enzyme and interleukin 1 beta from peripheral blood monocytes from patients with rheumatoid arthritis under a serum free condition. Ann Rheum Dis 49(3):172–176PubMedPubMedCentralCrossRef
78.
Sattar N, McCarey DW, Capell H, McInnes IB (2003) Explaining how “high-grade” systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation. 108(24):2957–2963PubMedCrossRef
79.
Fang L, Karakiulakis G, Roth M (2020) Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med 8(4):e21
80.
Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP et al (2011) Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford, England) 50(1):124–131CrossRef
81.
Listing J, Gerhold K, Zink A (2013) The risk of infections associated with rheumatoid arthritis, with its comorbidity and treatment. Rheumatology (Oxford, England) 52(1):53–61CrossRef
82.
83.
Dixon WG, Suissa S, Hudson M (2011) The association between systemic glucocorticoid therapy and the risk of infection in patients with rheumatoid arthritis: systematic review and meta-analyses. Arthritis Res Ther 13(4):R139PubMedPubMedCentralCrossRef
84.
Tang NL, Chan PK, Wong CK, To KF, Wu AK, Sung YM et al (2005) Early enhanced expression of interferon-inducible protein-10 (CXCL-10) and other chemokines predicts adverse outcome in severe acute respiratory syndrome. Clin Chem 51(12):2333–2340PubMedPubMedCentralCrossRef
85.
Hernández-Presa M, Bustos C, Ortego M, Tuñon J, Renedo G, Ruiz-Ortega M et al (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor-kappa B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation. 95(6):1532–1541PubMedCrossRef
86.
Fukuzawa M, Satoh J, Sagara M, Muto G, Muto Y, Nishimura S, Miyaguchi S, Qiang XL, Sakata Y, Nakazawa T, Ikehata F, Ohta S, Toyota T (1997) Angiotensin converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology. 36(1):49–55PubMedCrossRef
87.
Kitazono T, Padgett RC, Armstrong ML, Tompkins PK, Heistad DD (1995) Evidence that angiotensin II is present in human monocytes. Circulation. 91(4):1129–1134PubMedCrossRef
88.
Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M et al (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet (London, England) 354(9176):359–364CrossRef
89.
Dalbeth N, Edwards J, Fairchild S, Callan M, Hall FC (2005) The non-thiol angiotensin-converting enzyme inhibitor quinapril suppresses inflammatory arthritis. Rheumatology (Oxford, England) 44(1):24–31CrossRef
90.
Kashanian M, Eshraghi N, Rahimi M, Sheikhansari N, Javanmanesh FJJoO, Gynaecology (2020). Efficacy comparison of titrated oral solution of misoprostol and intravenous oxytocin on labour induction in women with full-term pregnancy ;40(1):20–4
91.
Bach J-FJEr (1994) Insulin-dependent diabetes mellitus as an autoimmune disease. 15(4):516–42
92.
Velloso LA, Eizirik DL, Cnop M (2013) Type 2 diabetes mellitus--an autoimmune disease? Nat Rev Endocrinol 9(12):750–755PubMedCrossRef
93.
Javaherforooshzadeh F, Amirpour I, Janatmakan F, Soltanzadeh MJA, medicine p (2018) Comparison of effects of melatonin and gabapentin on post operative anxiety and pain in lumbar spine surgery: A randomized clinical trial. 8(3)
94.
Efendić S, Luft R, Wajngot A (1984) Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 5(3):395–410PubMedCrossRef
95.
Hupfeld CJ, Olefsky JJEa, pediatric (2016) Type 2 diabetes mellitus: etiology, pathogenesis, and natural history. Endocrinology Adult and Pediatric: Diabetes Mellitus and Obesity E-Book. 2013 Jun 18:223
96.
Hodgson K, Morris J, Bridson T, Govan B, Rush C, Ketheesan N (2015) Immunological mechanisms contributing to the double burden of diabetes and intracellular bacterial infections. Immunology. 144(2):171–185PubMedPubMedCentralCrossRef
97.
Gupta R, Ghosh A, Singh AK, Misra A (2020) Clinical considerations for patients with diabetes in times of COVID-19 epidemic. Diabetes Metab Syndr 14(3):211–212PubMedPubMedCentralCrossRef
98.
Chen X, Hu W, Ling J, Mo P, Zhang Y, Jiang Q, Ma Z, Cao Q, Deng L, Song S, Zheng R (2020 Jan) Hypertension and diabetes delay the viral clearance in COVID-19 patients. medRxiv:1
99.
Deng SQ, Peng HJ (2020 Feb) Characteristics of and public health responses to the coronavirus disease 2019 outbreak in China. J Clin Med 9(2):575
100.
Tsukumo DM, Carvalho-Filho MA, Carvalheira JB, Prada PO, Hirabara SM, Schenka AA, et al. (2007) Loss-of-function mutation in Toll-like receptor 4 prevents diet-induced obesity and insulin resistance. Diabetes. 56(8):1986–98
101.
Ozcan U, Cao Q, Yilmaz E, Lee AH, Iwakoshi NN, Ozdelen E et al (2004) Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science (New York, NY) 306(5695):457–461CrossRef
102.
Gregor MF, Hotamisligil GS (2011) Inflammatory mechanisms in obesity. Annu Rev Immunol 29:415–445PubMedCrossRef
103.
Cnop M, Foufelle F, Velloso LA (2012) Endoplasmic reticulum stress, obesity and diabetes. Trends Mol Med 18(1):59–68PubMedCrossRef
104.
DeFronzo RA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin N Am 88(4):787–835 ix
105.
Defronzo RAJDr (1997) Pathogenesis of type 2 diabetes: metabolic and molecular implications for identifying diabetes genes. Diabetes Rev 5:177–266
106.
Shoelson SE, Lee J (2006) Goldfine ABJTJoci. Inflamm Insulin Resist 116(7):1793–1801
107.
Osborn O, Olefsky JM (2012) The cellular and signaling networks linking the immune system and metabolism in disease. Nat Med 18(3):363–374PubMedCrossRef
108.
Dietz W, Santos-Burgoa C (2020) Obesity and its implications for COVID-19 mortality. Obesity (Silver Spring, Md) 28(6):1005CrossRef
109.
Roca-Ho H, Riera M, Palau V, Pascual J, Soler MJ (2017) Characterization of ACE and ACE2 expression within different organs of the NOD mouse. Int J Mol Sci 18(3):563
110.
Wysocki J, Ye M, Soler MJ, Gurley SB, Xiao HD, Bernstein KE, Coffman TM, Chen S, Batlle D (2006) ACE and ACE2 activity in diabetic mice. Diabetes. 55(7):2132–2139PubMedCrossRef
111.
Chodavarapu H, Grobe N, Somineni HK, Salem ES, Madhu M, Elased KM (2013) Rosiglitazone treatment of type 2 diabetic db/db mice attenuates urinary albumin and angiotensin converting enzyme 2 excretion. PLoS One 8(4):e62833PubMedPubMedCentralCrossRef
112.
Pedersen KB, Chodavarapu H, Porretta C, Robinson LK, Lazartigues E (2015) Dynamics of ADAM17-mediated shedding of ACE2 applied to pancreatic islets of male db/db mice. Endocrinology. 156(12):4411–4425PubMedCrossRef
113.
Somineni HK, Boivin GP, Elased KM (2014) Daily exercise training protects against albuminuria and angiotensin converting enzyme 2 shedding in db/db diabetic mice. J Endocrinol 221(2):235–251PubMedPubMedCentralCrossRef
114.
Hamming I, van Goor H, Turner AJ, Rushworth CA, Michaud AA, Corvol P, Navis G (2008) Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats. Exp Physiol 93(5):631–638PubMedCrossRef
115.
Ghaffari H, Tavakoli A, Moradi A, Tabarraei A, Bokharaei-Salim F, Zahmatkeshan M, Farahmand M, Javanmard D, Kiani SJ, Esghaei M, Pirhajati-Mahabadi V, Monavari SH, Ataei-Pirkooh A (2019) Inhibition of H1N1 influenza virus infection by zinc oxide nanoparticles: another emerging application of nanomedicine. J Biomed Sci 26(1):70PubMedPubMedCentralCrossRef
116.
Shiota A, Yamamoto K, Ohishi M, Tatara Y, Ohnishi M, Maekawa Y, Iwamoto Y, Takeda M, Rakugi H (2010) Loss of ACE2 accelerates time-dependent glomerular and tubulointerstitial damage in streptozotocin-induced diabetic mice. Hypertens Res 33(4):298–307PubMedCrossRef
117.
Wong DW, Oudit GY, Reich H, Kassiri Z, Zhou J, Liu QC, Backx PH, Penninger JM, Herzenberg AM, Scholey JW (2007) Loss of angiotensin-converting enzyme-2 (Ace2) accelerates diabetic kidney injury. Am J Pathol 171(2):438–451PubMedPubMedCentralCrossRef
118.
Kassiri Z, Zhong J, Guo D, Basu R, Wang X, Liu PP, Scholey JW, Penninger JM, Oudit GY (2009) Loss of angiotensin-converting enzyme 2 accelerates maladaptive left ventricular remodeling in response to myocardial infarction. Circ Heart Fail 2(5):446–455PubMedCrossRef
119.
Rajaei E, Shahbazian N, Rezaeeyan H, Mohammadi AK, Hesam S, Zayeri ZDJCR (2019) The effect of lupus disease on the pregnant women and embryos: a retrospective study from 2010 to 2014. 38(11):3211–5
120.
Kashanian M, Eshraghi N, Sheikhansari N, Bordbar A, Khatami EJJoO, Gynaecology (2018) Comparison between two doses of betamethasone administration with 12 hours vs. 24 hours intervals on prevention of respiratory distress syndrome: a randomised trial. J Obstet Gynaecol 38(6):770–776
121.
Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM (2008) Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. Arthritis Rheum 59(8):1074–1081PubMedCrossRef
122.
Herman WH, Donner TW, Dudl RJ, Florez HJ, Fradkin JE, Professional Practice Committee of the American Diabetes Association (2016) Standards of medical care in diabetes-2016: summary of revisions. Diabetes Care 39(Suppl 1):S4–5
123.
Alawi LF, Emberesh SE, Owuor BA, Chodavarapu H, Fadnavis R, El-Amouri SS et al (2020) Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice. Phys Rep 8(3):e14364
124.
Perriot S, Mathias A, Perriard G, Canales M, Jonkmans N, Merienne N, Meunier C, el Kassar L, Perrier AL, Laplaud DA, Schluep M, Déglon N, du Pasquier R (2018) Human induced pluripotent stem cell-derived astrocytes are differentially activated by multiple sclerosis-associated cytokines. Stem Cell Rep 11(5):1199–1210CrossRef
125.
Lassmann H, van Horssen J, Mahad D (2012) Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 8(11):647–656PubMedCrossRef
126.
Maxeiner HG, Marion Schneider E, Kurfiss ST, Brettschneider J, Tumani H, Bechter K (2014) Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine. 69(1):62–67PubMedCrossRef
127.
Park H, Li Z, Yang XO, Chang SH, Nurieva R, Wang YH, Wang Y, Hood L, Zhu Z, Tian Q, Dong C (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6(11):1133–1141PubMedPubMedCentralCrossRef
128.
Yang XO, Panopoulos AD, Nurieva R, Chang SH, Wang D, Watowich SS, Dong C (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282(13):9358–9363PubMedCrossRef
129.
Nurieva R, Yang XO, Martinez G, Zhang Y, Panopoulos AD, Ma L, Schluns K, Tian Q, Watowich SS, Jetten AM, Dong C (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature. 448(7152):480–483PubMedCrossRef
130.
Wei L, Laurence A, Elias KM, O'Shea JJ (2007) IL-21 is produced by Th17 cells and drives IL-17 production in a STAT3-dependent manner. J Biol Chem 282(48):34605–34610PubMedCrossRef
131.
Chen M, Chen G, Nie H, Zhang X, Niu X, Zang YC et al (2009) Regulatory effects of IFN-beta on production of osteopontin and IL-17 by CD4+ T cells in MS. Eur J Immunol 39(9):2525–2536PubMedCrossRef
132.
Li X, O'Regan AW, Berman JS (2003) IFN-gamma induction of osteopontin expression in human monocytoid cells. J Interf Cytokine Res 23(5):259–265CrossRef
133.
O'Regan AW, Nau GJ, Chupp GL, Berman JS (2000) Osteopontin (Eta-1) in cell-mediated immunity: teaching an old dog new tricks. Immunol Today 21(10):475–478PubMedCrossRef
134.
Comabella M, Pericot I, Goertsches R, Nos C, Castillo M, Blas Navarro J, Río J, Montalban X (2005) Plasma osteopontin levels in multiple sclerosis. J Neuroimmunol 158(1–2):231–239PubMedCrossRef
135.
Vogt MH, Floris S, Killestein J, Knol DL, Smits M, Barkhof F et al (2004) Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. J Neuroimmunol 155(1–2):155–160PubMedCrossRef
136.
Khaibullin T, Ivanova V, Martynova E, Cherepnev G, Khabirov F, Granatov E, Rizvanov A, Khaiboullina S (2017) Elevated levels of proinflammatory cytokines in cerebrospinal fluid of multiple sclerosis patients. Front Immunol 8:531PubMedPubMedCentralCrossRef
137.
Miossec P, Kolls JK (2012) Targeting IL-17 and TH17 cells in chronic inflammation. Nat Rev Drug Discov 11(10):763–776PubMedCrossRef
138.
Brownlee W, Bourdette D, Broadley S, Killestein J, Ciccarelli O (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology. 94(22):949–952PubMedCrossRef
139.
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ (2020) COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England) 395(10229):1033–1034CrossRef
140.
Mayer L, Kappos L, Racke MK, Rammohan K, Traboulsee A, Hauser SL, Julian L, Köndgen H, Li C, Napieralski J, Zheng H, Wolinsky JS (2019) Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies. Mult Scler Relat Disord 30:236–243PubMedCrossRef
141.
Zhang C, Wu Z, Li JW, Zhao H, Wang GQ (2020) Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality. Int J Antimicrob Agents 55(5):105954PubMedPubMedCentralCrossRef
142.
Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X (2020) Effective treatment of severe COVID-19 patients with tocilizumab. Proceedings of the National Academy of Sciences 117(20):10970–10975
143.
Luo P, Liu Y, Qiu L, Liu X, Liu D, Li JJJomv (2020) Tocilizumab treatment in COVID-19: A single center experience. J Med Virol 92(7):814–818
144.
Guaraldi G, Meschiari M, Cozzi-Lepri A, Milic J, Tonelli R, Menozzi M, Franceschini E, Cuomo G, Orlando G, Borghi V, Santoro A (2020) Tocilizumab in patients with severe COVID-19: a retrospective cohort study. Lancet Rheumatol Aug 1;2(8):e474-84
145.
Radbel J, Narayanan N, Bhatt PJ (2020) Use of tocilizumab for COVID-19 infection-induced cytokine release syndrome: A cautionary case report. Chest
146.
Winkelmann A, Loebermann M, Reisinger EC, Hartung HP, Zettl UK (2016) Disease-modifying therapies and infectious risks in multiple sclerosis. Nat Rev Neurol 12(4):217–233PubMedCrossRef
147.
Zha L, Li S, Pan L, Tefsen B, Li Y, French N, Chen L, Yang G, Villanueva EV (2020) Corticosteroid treatment of patients with coronavirus disease 2019 (COVID‐19). Med J Aust 212(9):416–420
148.
Xu X-W, Wu X-X, Jiang X-G, Xu K-J, Ying L-J, Ma C-L, et al. (2020) Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. 36e8
149.
Selmaj K, Raine CS, Cannella B, Brosnan CF (1991) Identification of lymphotoxin and tumor necrosis factor in multiple sclerosis lesions. J Clin Invest 87(3):949–954PubMedPubMedCentralCrossRef
150.
Sicotte NL, Voskuhl RR (2001) Onset of multiple sclerosis associated with anti-TNF therapy. Neurology. 57(10):1885–1888PubMedCrossRef
151.
Shi Y, Wang Y, Shao C, Huang J, Gan J, Huang X, Bucci E, Piacentini M, Ippolito G, Melino G (2020) COVID-19 infection: the perspectives on immune responses. Cell Death Differ 27(5):1451–1454CrossRefPubMedPubMedCentral
152.
Jakimovski D, Kolb C, Ramanathan M, Zivadinov R, Weinstock-Guttman B (2018) Interferon β for multiple sclerosis. Cold Spring Harbor Perspectives in Medicine 8(11):a032003
153.
Lokugamage KG, Hage A, Schindewolf C, Rajsbaum R, Menachery VD (2020) SARS-CoV-2 is sensitive to type I interferon pretreatment. BioRxiv
154.
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K, Traboulsee A, Wolinsky JS, Arnold DL, Klingelschmitt G, Masterman D, Fontoura P, Belachew S, Chin P, Mairon N, Garren H, Kappos L, OPERA I and OPERA II Clinical Investigators (2017) Ocrelizumab versus interferon Beta-1a in relapsing multiple sclerosis. N Engl J Med 376(3):221–234PubMedCrossRef
155.
Novi G, Mikulska M, Briano F, Toscanini F, Tazza F, Uccelli A, Inglese M (2020) COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role? Mult Scler Relat Disord 42:102120PubMedPubMedCentralCrossRef
156.
Salzer J, Svenningsson R, Alping P, Novakova L, Björck A, Fink K, Islam-Jakobsson P, Malmeström C, Axelsson M, Vågberg M, Sundström P, Lycke J, Piehl F, Svenningsson A (2016) Rituximab in multiple sclerosis: a retrospective observational study on safety and efficacy. Neurology. 87(20):2074–2081PubMedPubMedCentralCrossRef
157.
Schwab N, Schneider-Hohendorf T, Posevitz V, Breuer J, Göbel K, Windhagen S et al (2013) L-selectin is a possible biomarker for individual PML risk in natalizumab-treated MS patients. Neurology. 81(10):865–871PubMedCrossRef
158.
Bright JJ, Du C, Sriram S (1999) Tyrphostin B42 inhibits IL-12-induced tyrosine phosphorylation and activation of Janus kinase-2 and prevents experimental allergic encephalomyelitis. J Immunol (Baltimore, Md : 1950) 162(10):6255–6262
159.
Jakhar D, Kaur I (2020) Potential of chloroquine and hydroxychloroquine to treat COVID-19 causes fears of shortages among people with systemic lupus erythematosus. Nat Med 26(5):632PubMedCrossRef
160.
Gatto M, Iaccarino L, Zen M, Doria A (2017) When to use belimumab in SLE. Expert Rev Clin Immunol 13(8):737–740PubMedCrossRef
161.
Venkiteshwaran A (2009) Tocilizumab mAbs. 1(5):432–8
162.
Huizinga TW, Fleischmann RM, Jasson M, Radin AR, van Adelsberg J, Fiore S et al (2014) Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY part a trial. Ann Rheum Dis 73(9):1626–1634PubMedCrossRef
163.
Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Posvar EL, Sedman AJ (2001) Quinapril and its metabolite quinaprilat in human milk. Br J Clin Pharmacol 51(5):478–481PubMedPubMedCentralCrossRef
164.
Aljada A, O’Connor L, Fu Y-Y, Mousa SAJA (2008) PPARγ ligands, rosiglitazone and pioglitazone, inhibit bFGF-and VEGF-mediated angiogenesis. 11(4):361–7
165.
Aubert R, Herrera V, Chen W, Haffner S, Pendergrass MJD (2010) Obesity, Metabolism. Rosiglitazone and pioglitazone increase fracture risk in women and men with type 2 diabetes. Diabetes Obes Metab 12(8):716–721
166.
167.
Pal R, Bhansali A (2020) COVID-19, diabetes mellitus and ACE2: the conundrum. Diabetes Res Clin Pract 162:108132
168.
Romaní-Pérez M, Outeiriño-Iglesias V, Moya CM, Santisteban P, González-Matías LC, Vigo E, Mallo F (2015) Activation of the GLP-1 receptor by Liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats. Endocrinology. 156(10):3559–3569PubMedCrossRef
Metadata
Title
The potential similarities of COVID-19 and autoimmune disease pathogenesis and therapeutic options: new insights approach
Authors
Sahar Najafi
Elham Rajaei
Rezvan Moallemian
Forough Nokhostin
Publication date
01-11-2020
Publisher
Springer International Publishing
Published in
Clinical Rheumatology / Issue 11/2020
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-020-05376-x

Other articles of this Issue 11/2020

Clinical Rheumatology 11/2020 Go to the issue

Letter to the Editor

Ultrasound versus dual-energy computed tomography in patients with different stages of acute gouty arthritis: methodological issues on diagnostic value

Original Article

Juvenile idiopathic arthritis in Southeast Asia: the Singapore experience over two decades

Letter to the Editor

COVID-19 reinfection or relapse: an intriguing dilemma

Review Article

Managing rheumatic diseases during COVID-19

Perspectives in Rheumatology

Moving towards online rheumatology education in the era of COVID-19

Clinical Image

Tumoral calcinosis in dermatomyositis
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits